Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events

ME Staff 8-k
-
0

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events
Item 8.01 Other Information.

As previously reported, on July 27, 2016, the United States District Court for the District of Massachusetts dismissed the suit brought by Amphastar Pharmaceuticals Inc. and its wholly-owned subsidiary International Medication Systems Ltd. (collectively, “Amphastar”) against Momenta Pharmaceuticals, Inc. (the “Company”) and Sandoz Inc. alleging that, in connection with filing the September 2011 patent infringement suit against Amphastar and Actavis Inc., the Company and Sandoz sought to prevent Amphastar from selling generic Enoxaparin Sodium Injection and thereby exclude competition for generic Enoxaparin Sodium Injection in violation of federal and California anti-trust laws and California unfair business laws. Also as previously reported, on August 25, 2016, Amphastar filed a notice of appeal from the dismissal with the United States Court of Appeals for the First Circuit. On March 6, 2017, the United States Court of Appeals for the First Circuit reversed the District Court’s dismissal and remanded the suit to the District Court for further proceedings.


About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session 00.00 at 14.30 with 655,874 shares trading hands.